Screening for advanced liver scarring in people with HIV
Part of Digestive system clinical trials.
This study looks at how common advanced liver scarring (advanced fibrosis) is in people living with HIV. It may help doctors better understand liver risk in everyday care and guide future prevention.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to give informed consent (agree to join the study).
- You must be over 18 years old.
- You cannot be pregnant at the time of joining.
- The study is not for people whose health is expected to limit survival to less than 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well primary care doctors can screen for advanced liver scarring in people with fatty liver from non-alcohol causes or from alcohol use. It may help find liver problems earlier so you can get the right follow-up.
This study tests a way to find liver scarring (fibrosis) early in people who have risk factors like being overweight, having type 2 diabetes, or drinking alcohol heavily. Early detection may help prevent serious liver damage.
This study checks people who are at higher risk for liver scarring by using noninvasive tests. If those tests suggest significant scarring, the study may consider further testing, but not everyone will need a biopsy.
This study follows people with HIV who also have fatty liver disease and checks their health over time. It may help by improving monitoring and care planning, especially using ultrasound scans and regular follow-up.
This study looks at what factors predict liver inflammation, scarring (fibrosis), and health outcomes in people with long-term hepatitis B or fatty liver disease. The goal is to better understand who is more likely to worsen over time.
This study compares two non-invasive approaches to diagnose advanced liver scarring in people with non-alcohol-related fatty liver disease (NAFLD). It may help confirm which test strategy finds advanced scarring without needing a biopsy for everyone.
Hear when a new Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.